2-(4-ethylphenoxy)-N-methylethanamine | 915921-60-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-(4-ethylphenoxy)-N-methylethanamine
• CAS: 915921-60-7
• 化学式: C₁₁H₁₇NO
• 分子量: 179.26
• InChiKey: OQCZVYNNBMVDGO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS<br/>[FR] COMPOSÉS ET PROCÉDÉS POUR LA DÉGRADATION CIBLÉE DE PROTÉINES CONTENANT UN BROMODOMAINE
  申请人：ARVINAS INC

  公开号：WO2017030814A1

  公开（公告）日：2017-02-23

  The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.

  本发明涉及双功能化合物，其作为靶向泛素化的调节剂具有实用性，特别是根据本发明抑制各种多肽和其他蛋白质的化合物。具体而言，本发明涉及一端含有结合泛素连接酶的VHL配体，另一端含有结合靶蛋白的基团的化合物，使得靶蛋白靠近泛素连接酶以促使该蛋白的降解（和抑制）。根据本发明的化合物表现出与靶向多肽的降解/抑制一致的广泛的药理活性。
• HETEROCYCLIC COMPOUNDS AND USES THEREOF
  申请人：giraFpharma LLC

  公开号：US20190106436A1

  公开（公告）日：2019-04-11

  Heterocyclic compounds as Wee1 inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

  提供了作为Wee1抑制剂的杂环化合物。这些化合物可能被用作治疗药物，用于治疗疾病，并且可能在肿瘤学中发挥特定作用。
• LIBRARIES OF DIVERSE MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME
  申请人：CYCLENIUM PHARMA INC.

  公开号：US20190153620A1

  公开（公告）日：2019-05-23

  The present disclosure relates to novel macrocyclic compounds and libraries thereof that are useful as research tools for drug discovery efforts. This disclosure also relates to methods of preparing these compounds and libraries and methods of using these libraries, such as in high throughput screening. In particular, these libraries are useful for evaluation of bioactivity at existing and newly identified pharmacologically relevant targets, including G protein-coupled receptors, nuclear receptors, enzymes, ion channels, transporters, transcription factors, protein-protein interactions and nucleic acid-protein interactions. As such, these libraries can be applied to the search for new pharmaceutical agents for the treatment and prevention of a range of medical conditions.

  本公开涉及新颖的大环化合物及其库，这些化合物可作为药物发现工作的研究工具。本公开还涉及制备这些化合物和库的方法，以及使用这些库的方法，例如在高通量筛选中的应用。特别是，这些库可用于评估现有和新鉴定的药理相关靶点的生物活性，包括G蛋白偶联受体、核受体、酶、离子通道、转运蛋白、转录因子、蛋白质相互作用和核酸-蛋白质相互作用。因此，这些库可应用于寻找用于治疗和预防各种医疗状况的新药物。
• [EN] HETEROCYCLIC KINASE INHIBITORS<br/>[FR] INHIBITEURS HÉTÉROCYCLIQUES DE LA KINASE
  申请人：SELEXAGEN THERAPEUTICS INC

  公开号：WO2011038261A1

  公开（公告）日：2011-03-31

  Described herein are compounds, pharmaceutical compositions and methods for the inhibition of kinase signaling mediated by the kinases A-RAF, B-RAF,C-RAF, p38, or GSK3β.. Said compounds, pharmaceutical compositions and methods have utility in the treatment of human disease and disorders.

  本文描述了一些化合物、药物组合物和方法，用于抑制由A-RAF、B-RAF、C-RAF、p38或GSK3β激酶介导的激酶信号传导。这些化合物、药物组合物和方法在人类疾病和疾病的治疗中有用。
• COMPOUNDS AND THEIR USES 707
  申请人：Hallam Matthew

  公开号：US20090023746A1

  公开（公告）日：2009-01-22

  The present invention relates to isoquinolinone derivatives of formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are as herein defined; processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明涉及公式（I）的异喹啉酮衍生物：其中R1，R2，R3，R4，R5，R6和R7如本文所定义；它们的制备方法，含有它们的制药组合物以及它们在治疗中的用途。